The PD-L1 inhibitor atezolizumab combined with nab-paclitaxel became the first immunotherapy regimen to show significant PFS and OS benefits in the first-line treatment of PD-L1-positive (≥1% tumor area) metastatic TNBC. This evidence concerns the gene CD274 and neoplasm.